Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT06744478
Enrolling by invitation Observational

Assessing the Magnitude of Anisometropia in Patients Wearing Misight 1 Day Contact Lens

NCT06744478 · tracked via the Priya Life Science Taiwan tracker
Phase
Observational
Started
2025-01-01
Last updated
2024-12-20

Condition(s) studied

MyopiaAnisometropia

Investigational drug(s) / intervention(s)

Misight 1 Day Contact Lens

Misight 1 Day Contact Lens: Misight 1 Day Contact Lens wearing for myopia control

Study summary

The effectiveness of Misight 1 Day Contact Lens in retarding anisometropic progression has not been investigated before. This study is aimed to elucidate the efficacy of Misight 1 Day Contact Lens for anisometropia control.

Eligibility

Sex
ALL
Min age
8 Years
Max age
23 Years
Healthy volunteers
No
Inclusion Criteria: * 8-23 years old children diagnosed with anisometropia and are willing to accept MiSight® 1 Day contact lens wearing treatment. * No congenital eye diseases or eye diseases such as strabismus and amblyopia. * Those who have been stated to be willing to participate in the program for at least 24 months and accept various evaluations. Exclusion Criteria: * Ocular surface disease( dry eye, keratoconus..) * Allergy to contact lens * Received eye surgery before * The cornea is infected (bacterial, fungal or viral infection). * Strabismus * Premature birth

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shang-Yen WU Hualien City Taiwan

More Buddhist Tzu Chi General Hospital trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06744478 on ClinicalTrials.gov ↗ ← All trials in Taiwan